Tharimmune Files 8-K/A Amendment
Ticker: CNTN · Form: 8-K/A · Filed: Aug 26, 2025 · CIK: 1861657
| Field | Detail |
|---|---|
| Company | Tharimmune, INC. (CNTN) |
| Form Type | 8-K/A |
| Filed Date | Aug 26, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $5.35 million, $4.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, material-agreement
TL;DR
Tharimmune filed an amendment to a previous 8-K, updating details on a material agreement.
AI Summary
Tharimmune, Inc. filed an 8-K/A on August 26, 2025, to amend a previous filing. The amendment pertains to Item 1.01, Entry into a Material Definitive Agreement, and Item 9.01, Financial Statements and Exhibits. Specific details of the material definitive agreement are not provided in this excerpt, but the filing indicates a need to update or correct information previously submitted.
Why It Matters
This amendment indicates Tharimmune, Inc. is updating or correcting previously filed information regarding a material definitive agreement, which could impact the understanding of its business dealings.
Risk Assessment
Risk Level: medium — Amendments to material definitive agreements can signal changes or corrections in business operations that may affect the company's financial health or strategic direction.
Key Players & Entities
- Tharimmune, Inc. (company) — Registrant
- August 26, 2025 (date) — Date of Report
- 001-41210 (other) — Commission File Number
- 84-2642541 (other) — I. R. S. Employer Identification No.
FAQ
What specific material definitive agreement is Tharimmune, Inc. amending?
The provided excerpt does not specify the details of the material definitive agreement being amended under Item 1.01.
What is the purpose of this 8-K/A filing?
The purpose of this 8-K/A filing is to amend a previous report, specifically concerning Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits).
When was the original event or filing that this 8-K/A amends?
The filing date of this 8-K/A is August 26, 2025, and it amends a previous report, but the date of the original event is not specified in this excerpt.
What are the principal executive offices of Tharimmune, Inc.?
The principal executive offices of Tharimmune, Inc. are located at 34 Shrewsbury Avenue, Suite 1C, Red Bank, NJ 07701.
What is Tharimmune, Inc.'s telephone number?
Tharimmune, Inc.'s telephone number is (732) 889-3111.
Filing Stats: 733 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2025-08-26 17:24:20
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value THAR The Nasdaq Stock Mar
- $5.35 million — ration Statement (as defined below), of $5.35 million of the Company's securities (the "Secur
- $4.50 — common stock equivalents) at a price of $4.50 per share of Common Stock. In relatio
Filing Documents
- form8-ka.htm (8-K/A) — 42KB
- ex4-1.htm (EX-4.1) — 95KB
- ex5-1.htm (EX-5.1) — 23KB
- ex10-1.htm (EX-10.1) — 241KB
- ex10-2.htm (EX-10.2) — 86KB
- ex5-1_001.jpg (GRAPHIC) — 4KB
- 0001641172-25-025585.txt ( ) — 753KB
- thar-20250826.xsd (EX-101.SCH) — 3KB
- thar-20250826_lab.xml (EX-101.LAB) — 33KB
- thar-20250826_pre.xml (EX-101.PRE) — 22KB
- form8-ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 26, 2025 Tharimmune, Inc. /s/ Sireesh Appajosyula Sireesh Appajosyula Chief Executive Officer